




RealRate

PHARMACEUTICAL 2020

DiaMedica Therapeutics Inc. Rank 214 of 358





RealRate

PHARMACEUTICAL 2020

DiaMedica Therapeutics Inc. Rank 214 of 358



The relative strengths and weaknesses of DiaMedica Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DiaMedica Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 59% points. The greatest weakness of DiaMedica Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 10% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	8,836
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,318
Liabilities, Non-Current	118
Other Assets	153
Other Compr. Net Income	2.0
Other Expenses	31
Other Liabilities	0
Other Net Income	975
Other Revenues	0
Property and Equipment	64
Research and Development	7,900
Selling, General and Administrative Expense	3,693

Output Variable	Value in 1000 USD
Assets	9,053
Liabilities	1,436
Expenses	11,624
Revenues	0
Stockholders Equity	7,617
Net Income	-10,649
Comprehensive Net Income	-10,648
Economic Capital Ratio	47%